Dose-intense etoposide-cyclophosphamide without stem cell transplantation for patients with intermediate and high cytogenetic risk primary refractory and relapsed acute myeloid leukemia.

Abstract excerpt

Dose-intense etoposide-cyclophosphamide (D-I ECy) without stem cell transplantation has been used in salvage regimens for the treatment of resistant acute myeloid leukemia(AML). Previous D-I ECy studies classified AML according to FAB-criteria, before cytogenetic risk was found to be a major determinant of prognosis. Currently the influence of karyotype on response to D-I ECy is unknown. Thus, an observational...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cyclophosphamide
• Share to Cytogenetic Analysis